BioInformant

Your Global Leader in Stem Cell Market Research

Home » CAR-T » Page 5

CAR-T Manufacturing | Novartis Selects French CDMO CELLforCURE

By Leave a Comment

CELLforCURE is a French pharmaceutical group that is authorized to do CAR-T manufacturing at its bioproduction site in Les Ulis (Essonne). CELLforCURE holds two Good Manufacturing Practice (GMP) certificates that allows it to manufacture experimental and commercial cell and gene therapies.

On July 10, 2018, CELLforCURE signed an agreement to manufacture CAR-T products for Novartis. Under the terms of the agreement, CELLforCURE will produce cancer CAR-T therapies (“chimeric antigen receptor T-cells”).

Production is scheduled to begin in 2019 following transfer of Novartis’ CAR-T manufacturing technology to CELLforCURE. [Read more…]

Mesoblast & Cartherics to Produce Allogeneic CAR-T Cells from Gene-Edited iPS Cells

By Leave a Comment

Mesoblast Partners With Cartherics to Develop ’off-the-shelf’ Cell-based Immunotherapies for Solid Cancers

Relapsed Ovarian and Gastric Cancers Initial Targets for Allogeneic CAR-T Cells

NEW YORK and MELBOURNE, Australia, May 29, 2018 — Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has entered into a partnership with Cartherics Pty Ltd to develop allogeneic ‘off-the-shelf’ CAR-T cells armed with multiple targeting receptors for use in solid cancers. Off the shelf CAR-T therapies have the potential to reduce costs dramatically and open up this very effective treatment to millions of cancer patients across the world. The initial targets are relapsed ovarian and gastric cancers. Mesoblast and Cartherics will jointly own the intellectual property produced using their combined technologies. [Read more…]

Kite Pharma Execs Form Allogene with Pfizer’s CAR-T Assets and $300M

By Leave a Comment

  • Creates alliance with Allogene Therapeutics, a biotechnology company co-founded and led by former executives of Kite Pharma that is positioned to expedite the development of allogeneic CAR T cell therapy

  • Allogene Therapeutics, a Two River portfolio company, was formed with one of the largest Series A financings in biotechnology of $300 million from a premier investment consortium that includes TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer and Pfizer

  • Pfizer will hold a 25 percent ownership stake in Allogene Therapeutics

NEW YORK & SOUTH SAN FRANCISCO–Pfizer Inc. (NYSE:PFE) and Allogene Therapeutics, Inc. (Allogene) today announced that the two companies have entered into an asset contribution agreement for Pfizer’s portfolio of assets related to allogeneic chimeric antigen receptor T cell (CAR T) therapy, an investigational immune cell therapy approach to treating cancer.
[Read more…]

Cesca Therapeutics is making BIG moves to dominate the CAR-T space

By Leave a Comment

Cesca Therapeutics

Cesca Therapeutics is making big moves to become a player in the CAR-T space. In recent months it filed a a patent application for innovation to its CAR-TXpress™ technology, signed a license agreement with China’s IncoCell Tianjin Ltd. for CAR-T related CDMO services in Asia, and is continuing development of Thermogenesis’ novel CAR-TXpress platform.

The company also recently announced the launch of its 2nd gen AXP® II system for isolating and collecting hematopoietic stem cells (HSCs) from umbilical cord blood and peripheral blood. Since the launch of its first AXP® system, Cesca has been a leader is cord blood processing technologies.

[Read more…]

BioInformant's World-Class Clients